FIELD: medicine.
SUBSTANCE: invention concerns using comenic acid calcium salt for preventing and treating neurodegenerative diseases caused by oxidative brain damage, taken once a day daily orally on an empty stomach for 3 days. When implementing the declared application, calcium comenate has shown both the antioxidant stress-protective action, and also the pronounced neutrophic action in a combination with the neuritic growth recovery to a reference values; calcium comenate has no toxicity.
EFFECT: higher effectiveness.
5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEUROPROTECTIVE PHARMACEUTICAL AGENT | 2013 |
|
RU2528914C1 |
| ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE PHARMACOLOGICAL AGENT POTASSIUM COMENATE | 2012 |
|
RU2514632C1 |
| ANTIOXIDANT, STRESS AND NEUROPROTECTIVE PHARMACOLOGICAL AGENT SODIUM COMENATE | 2012 |
|
RU2506078C1 |
| METHOD FOR PREPARING LITHIUM SALT OF COMENIC ACID AND USING IT AS ANTIOXIDANT, STRESS- AND NEUROPROTECTIVE AGENT | 2011 |
|
RU2477722C1 |
| NEUROPROTECTIVE AGENT | 2016 |
|
RU2614697C1 |
| METHOD OF PREVENTING AND CORRECTION OF DISTURBANCES OF MAIN FUNCTIONS OF CENTRAL NERVOUS SYSTEM IN CASE OF LEAD INTOXICATION IN PRENATAL AND EARLY POSTPARTUM PERIOD | 2009 |
|
RU2410107C1 |
| METHOD FOR PREVENTING AND CORRECTING METABOLIC AND FUNCTIONAL DISORDERS OF THE CENTRAL NERVOUS SYSTEM UNDER STRESS CONDITIONS | 2019 |
|
RU2717107C1 |
| COMBINED DRUG FOR PRIMARY NEUROPROTECTION | 2017 |
|
RU2636616C1 |
| METHOD FOR PREVENTION AND TREATMENT OF CARBOHYDRATE AND LIPID METABOLISM DISORDER IN METABOLIC SYNDROME AND ENCEPHALOPATHY, USE OF TETRAPEPTIDE AND PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF SUCH DISORDERS | 2012 |
|
RU2480234C1 |
| DONECOPRID AS A NEUROPROTECTIVE AGENT IN THE TREATMENT OF NEURODEGERATIVE DISEASES | 2019 |
|
RU2800802C2 |
